Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma

被引：26

作者：

DeLeon, Thomas T. ^{[1
]}

Ahn, Daniel H. ^{[1
]}

Bogenberger, James M. ^{[1
]}

Anastasiadis, Panos Z. ^{[2
]}

Arora, Mansi ^{[1
]}

Ramanathan, Ramesh K. ^{[1
]}

Aqel, Bashar A. ^{[3
]}

Vasmatzis, George ^{[4
]}

Truty, Mark J. ^{[5
]}

Oklu, Rahmi ^{[6
]}

Bekaii-Saab, Tanios S. ^{[1
]}

Borad, Mitesh J. ^{[1
]}

机构：

[1] Mayo Clin, Dept Med, Div Hematol Oncol, Scottsdale, AZ 85259 USA

[2] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA

[3] Mayo Clin, Dept Med, Div Gastroenterol & Hepatol, Scottsdale, AZ 85259 USA

[4] Mayo Clin, Dept Lab Med & Pathol, Dept Mol Med, Rochester, MN 55902 USA

[5] Mayo Clin, Dept Surg, Div Hepatobiliary & Pancreat Surg, Rochester, MN 55902 USA

[6] Mayo Clin, Dept Radiol, Div Intervent Radiol, Scottsdale, AZ 85259 USA

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 06期

关键词：

biomarkers; cholangiocarcinoma; gallbladder cancer; hepatocellular cancer; immunotherapy; targeted therapy; GROWTH-FACTOR-RECEPTOR; TELOMERE TERMINAL TRANSFERASE; C-MET EXPRESSION; INTRAHEPATIC CHOLANGIOCARCINOMA; MUTATIONAL LANDSCAPE; PROGNOSTIC-SIGNIFICANCE; NEGATIVE REGULATOR; CLINICAL-RESPONSE; TUMOR-SUPPRESSOR; RISING INCIDENCE;

D O I：

10.2217/fon-2017-0451

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Worldwide hepatobiliary cancers are the second leading cause of cancer related death. Despite their relevance, hepatobiliary cancers have a paucity of approved systemic therapy options. However, there are a number of emerging therapeutic biomarkers and therapeutic concepts that show promise. In hepatocellular carcinoma, nivolumab appears particularly promising and recently received US FDA approval. In intrahepatic cholangiocarcinoma, therapies targeting FGFR2 and IDH1 and immune checkpoint inhibitors are the furthest along and generating the most excitement. There are additional biomarkers that merit further exploration in hepatobiliary cancers including FGF19, ERRFI1, TERT, BAP1, BRAF, CDKN2A, tumor mutational burden and ERBB2 (HER2/neu). Development of new and innovative therapies would help address the unmet need for effective systemic therapies in advanced and metastatic hepatobiliary cancers.

引用

页码：553 / 566

页数：14

共 117 条

[81] Phase II study of erlotinib in patients with advanced biliary cancer [J].

Philip, Philip A. ;

Mahoney, Michelle R. ;

Allmer, Cristine ;

Thomas, James ;

Pitot, Henry C. ;

Kim, George ;

Donehower, Ross C. ;

Fitch, Tom ;

Picus, Joel ;

Erlichman, Charles .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3069-3074

[82] Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas [J].

Pignochino, Ymera ;

Sarotto, Ivana ;

Peraldo-Neia, Caterina ;

Penachioni, Junia Y. ;

Cavalloni, Giuliana ;

Migliardi, Giorgia ;

Casorzo, Laura ;

Chiorino, Giovanna ;

Risio, Mauro ;

Bardelli, Alberto ;

Aglietta, Massimo ;

Leone, Francesco .

BMC CANCER, 2010, 10

[83] Mitogen-Inducible Gene-6 is a Negative Regulator of Epidermal Growth Factor Receptor Signaling in Hepatocytes and Human Hepatocellular Carcinoma [J].

Reschke, Markus ;

Ferby, Ingvar ;

Stepniak, Ewa ;

Seitzer, Nina ;

Horst, David ;

Wagner, Erwin F. ;

Ullrich, Axel .

HEPATOLOGY, 2010, 51 (04) :1383-1390

[84] Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma A Multi-institutional Analysis of 434 Patients [J].

Ribero, Dario ;

Pinna, Antonio Daniele ;

Guglielmi, Alfredo ;

Ponti, Antonio ;

Nuzzo, Gennaro ;

Giulini, Stefano Maria ;

Aldrighetti, Luca ;

Calise, Fulvio ;

Gerunda, Giorgio Enrico ;

Tomatis, Mariano ;

Amisano, Marco ;

Berloco, Pasquale ;

Torzilli, Guido ;

Capussotti, Lorenzo .

ARCHIVES OF SURGERY, 2012, 147 (12) :1107-1113

[85] Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial. [J].

Rimassa, Lorenza ;

Assenat, Eric ;

Peck-Radosavljevic, Markus ;

Zagonel, Vittorina ;

Pracht, Marc ;

Caremoli, Elena Rota ;

Mathurin, Philippe ;

Harris, William Proctor ;

Bolondi, Luigi ;

Reig, Maria ;

Damjanov, Nevena ;

Daniele, Bruno ;

Porta, Camillo ;

Mazzaferro, Vincenzo ;

Abbadessa, Giovanni ;

Schwartz, Brian E. ;

Lamar, Maria ;

Goldberg, Terri Robin ;

Santoro, Armando ;

Bruix, Jordi .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[86] Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer [J].

Rizvi, Naiyer A. ;

Hellmann, Matthew D. ;

Snyder, Alexandra ;

Kvistborg, Pia ;

Makarov, Vladimir ;

Havel, Jonathan J. ;

Lee, William ;

Yuan, Jianda ;

Wong, Phillip ;

Ho, Teresa S. ;

Miller, Martin L. ;

Rekhtman, Natasha ;

Moreira, Andre L. ;

Ibrahim, Fawzia ;

Bruggeman, Cameron ;

Gasmi, Billel ;

Zappasodi, Roberta ;

Maeda, Yuka ;

Sander, Chris ;

Garon, Edward B. ;

Merghoub, Taha ;

Wolchok, Jedd D. ;

Schumacher, Ton N. ;

Chan, Timothy A. .

SCIENCE, 2015, 348 (6230) :124-128

[87]

Roa Ivan, 2014, Gastrointest Cancer Res, V7, P42

[88] Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial [J].

Rosenberg, Jonathan E. ;

Hoffman-Censits, Jean ;

Powles, Tom ;

van der Heijden, Michiel S. ;

Balar, Arjun V. ;

Necchi, Andrea ;

Dawson, Nancy ;

O'Donnell, Peter H. ;

Balmanoukian, Ani ;

Loriot, Yohann ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Grivas, Petros ;

Joseph, Richard W. ;

Galsky, Matthew D. ;

Fleming, Mark T. ;

Petrylak, Daniel P. ;

Perez-Gracia, Jose Luis ;

Burris, Howard A. ;

Castellano, Daniel ;

Canil, Christina ;

Bellmunt, Joaquim ;

Bajorin, Dean ;

Nickles, Dorothee ;

Bourgon, Richard ;

Frampton, Garrett M. ;

Cui, Na ;

Mariathasan, Sanjeev ;

Abidoye, Oyewale ;

Fine, Gregg D. ;

Dreicer, Robert .

LANCET, 2016, 387 (10031) :1909-1920

[89] New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing [J].

Ross, Jeffrey S. ;

Wang, Kai ;

Gay, Laurie ;

Al-Rohil, Rami ;

Rand, Janne V. ;

Jones, David M. ;

Lee, Hwa J. ;

Sheehan, Christine E. ;

Otto, Geoff A. ;

Palmer, Gary ;

Yelensky, Roman ;

Lipson, Doron ;

Morosini, Deborah ;

Hawryluk, Matthew ;

Catenacci, Daniel V. T. ;

Miller, Vincent A. ;

Churi, Chaitanya ;

Ali, Siraj ;

Stephens, Philip J. .

ONCOLOGIST, 2014, 19 (03) :235-242

[90] PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma [J].

Sabbatino, Francesco ;

Villani, Vincenzo ;

Yearley, Jennifer H. ;

Deshpande, Vikram ;

Cai, Lei ;

Konstantinidis, Ioannis T. ;

Moon, Christina ;

Nota, Sjoerd ;

Wang, Yangyang ;

Al-Sukaini, Ahmad ;

Zhu, Andrew X. ;

Goyal, Lipika ;

Ting, David T. ;

Bardeesy, Nabeel ;

Hong, Theodore S. ;

Castillo, Carlos Fernandez-Del ;

Tanabe, Kenneth K. ;

Lillemoe, Keith D. ;

Ferrone, Soldano ;

Ferrone, Cristina R. .

CLINICAL CANCER RESEARCH, 2016, 22 (02) :470-478

← 3 4 5 6 7 8 9 10 11 12 →